Tailoring antiseizure treatment with a wearable device: A proof-of-concept study in absence epilepsy

被引:0
|
作者
Macea, Jaiver [1 ]
Chatzichristos, Christos [2 ]
Bhagubai, Miguel [2 ]
De Vos, Maarten [2 ,3 ]
Van Paesschen, Wim [1 ,4 ]
机构
[1] Katholieke Univ Leuven, Leuven Brain Inst, Dept Neurosci, Lab Epilepsy Res, ON 5 Herestr 49,Bus 1022, B-3000 Leuven, Belgium
[2] Katholieke Univ Leuven, STADIUS Ctr Dynam Syst Signal Proc & Data Analyt, Dept Elect Engn, Leuven, Belgium
[3] Katholieke Univ Leuven, Dept Dev & Regenerat, Woman & Child, Leuven, Belgium
[4] Leuven Univ Hosp, Dept Neurol, Leuven, Belgium
关键词
absence seizures; antiseizure medication; idiopathic generalized epilepsy; personalized medicine; wearable electronic devices; SEIZURE DETECTION; VALPROIC ACID; CHILDHOOD; EEG; LAMOTRIGINE; GUIDELINE;
D O I
10.1111/epi.18384
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
ObjectiveTypical absence seizures are underreported. We aimed to improve patient care using a wearable electroencephalograph (wEEG) at home and assess a machine learning (ML) pipeline for absence detection. MethodsPatients with typical absences used a wEEG device 12-24 h 1 week after antiseizure medication (ASM) adjustments. Three-hertz generalized spike-wave discharges (SWDs) >= 3 s were used as absence surrogates. After manual inspection, we used the results to guide medical treatment. The outcomes were seizure freedom, number of consecutive measurements without relapse, and side effects. Afterward, we used the ML pipeline on the recordings, and a neurologist reviewed the output. Review time and diagnostic performance were compared with manual inspection. ResultsNineteen patients (12 female, median age = 24 years) were followed for a median of 5 months (range = 1-12). The median recording time for each session was 21.3 h (range = 10-24). Fifteen patients (79%) were seizure-free during the last measurement, including seven of 11 (63%) diagnosed with refractory epilepsy. Ten patients relapsed after a median of 1-2 recordings (range = 1-6) without 3-Hz SWDs. Side effects occurred in 21% of patients. Manual file inspection identified 806 3-Hz SWDs of >= 3 s. The ML pipeline reduced a neurologist's median review time for 24-h wEEG from 27 (range = 10-45) to 4.3 min (range = .1-10), with a sensitivity, precision, F1-score, and false positives per hour of .8, .95, .87, and .007, respectively. SignificanceHome-based wEEG allows patient monitoring after ASM adjustments, improving absence seizure management. The ML-based pipeline performed well and was crucial in reducing review time.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Wearable device for iontophoretic treatment and monitoring of pressure ulcers: Proof-of-concept
    Chaudon, M. -J.
    Hulea, O.
    Yakoub, A.
    Monnier, P.
    Saadaoui, M.
    MEDICAL ENGINEERING & PHYSICS, 2022, 107
  • [2] Network coupling and surgical treatment response in temporal lobe epilepsy: A proof-of-concept study
    Chang, Allen J.
    Roth, Rebecca W.
    Gong, Ruxue
    Gross, Robert E.
    Harmsen, Irene
    Parashos, Alexandra
    Revell, Andrew
    Davis, Kathryn A.
    Bonilha, Leonardo
    Gleichgerrcht, Ezequiel
    EPILEPSY & BEHAVIOR, 2023, 149
  • [3] Prophylactic treatment in menstrual migraine: A proof-of-concept study
    Wickmann, Franziska
    Stephani, Caspar
    Czesnik, Dirk
    Klinker, Florian
    Timaeus, Charles
    Chaieb, Leila
    Paulus, Walter
    Antal, Andrea
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 354 (1-2) : 103 - 109
  • [4] Using Passive BCI for Personalization of Assistive Wearable Devices: A Proof-of-Concept Study
    Mahmoudi, Asghar
    Khosrotabar, Morteza
    Gramann, Klaus
    Rinderknecht, Stephan
    Sharbafi, Maziar A.
    IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING, 2025, 33 : 476 - 487
  • [5] A Device Agnostic Approach to Predict Children's Activity from Consumer Wearable Accelerometer Data: A Proof-of-Concept Study
    Weaver, R. Glenn
    White, James
    Finnegan, Olivia
    Nelakuditi, Srihari
    Zhu, Xuanxuan
    Burkart, Sarah
    Beets, Michael
    Brown, Trey
    Pate, Russ
    Welk, Gregory J.
    Zambotti, Massimiliano D. E.
    Ghosal, Rahul
    Wang, Yuan
    Armstrong, Bridget
    Adams, Elizabeth l.
    Reesor-oyer, Layton
    Pfledderer, Christopher D.
    Bastyr, Meghan
    Von Klinggraeff, Lauren
    Parker, Hannah
    MEDICINE & SCIENCE IN SPORTS & EXERCISE, 2024, 56 (02) : 370 - 379
  • [6] A proof-of-concept study of the VeinScrew: A new percutaneous venous closure device
    Boersma, Doeke
    de Borst, Gert Jan
    Moll, Frans L.
    VASCULAR, 2017, 25 (01) : 105 - 109
  • [7] Pilot study of trigeminal nerve stimulation (TNS) for epilepsy: A proof-of-concept trial
    DeGiorgio, Christopher M.
    Shewmon, Alan
    Murray, Diane
    Whitehurst, Todd
    EPILEPSIA, 2006, 47 (07) : 1213 - 1215
  • [8] A Wireless Neuroprosthesis for Patients with Drug-refractory Epilepsy: A Proof-of-Concept Study
    Romanelli, Pantaleo
    Valiante, Taufik A.
    Seri, Stefano
    Puttilli, Cosimo
    Picciafuoco, Mauro
    Jakobs, Martin
    Lozano, Andres
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (10)
  • [9] Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study
    Wong, Vincent Wai-Sun
    Wong, Grace Lai-Hung
    Chim, Angel Mei-Ling
    Chu, Winnie Chiu-Wing
    Yeung, David Ka-Wai
    Li, Kevin Chi-To
    Chan, Henry Lik-Yuen
    ANNALS OF HEPATOLOGY, 2013, 12 (02) : 256 - 262
  • [10] Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study
    Crestani, B.
    Chapron, J.
    Wallaert, B.
    Bergot, E.
    Delaval, P.
    Israel-Biet, D.
    Lacronique, J.
    Monnet, I.
    Reynaud-Gaubert, M.
    Tazi, A.
    Lebtahi, R.
    Debray, M-P.
    Brauner, M.
    Dehoux, M.
    Dornic, Q.
    Aubier, M.
    Mentre, F.
    Duval, X.
    EUROPEAN RESPIRATORY JOURNAL, 2012, 39 (03) : 772 - 775